FogPharma a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,".

FogPharma's mission is to drastically reduce the burden of disease on patients and their families by inventing new types of drugs that squelch abnormal physiological processes in ways previously imagined but considered unattainable.

FogPharma was founded in 2016 by Gregory Verdine, WeiQing Zhou and Sir David Lane. The company is headquartered in Cambridge, Massachusetts.

FogPharma’s lead Helicon polypeptide development candidate, FOG-001, a first-and-only-in-class direct TCF-blocking β-catenin inhibitor. Dysregulation of the Wnt/β-catenin signaling pathway has been shown to occur in at least 20% of all human cancers.

FogPharma's Helicon peptide drug discovery engine integrates directed evolution, proprietary helix hyperstabilization chemistry, highly multiplexed drug optimization technology, AI including deep learning and ML, structure-based drug discovery, and multiscale manufacturing.

FogPharma is also advancing other first-in-class programs against important, biologically validated cancer targets that have remained elusive to other approaches including TEAD, NRAS, Pan-KRAS, ERG and Cyclin E1.

FogPharma is backed by GV, ARCH Venture Partners, venBio Partners, Fidelity Management & Research Compan, Deerfield Management, Cormorant Asset Management, Casdin Capital, 6 Dimensions Capital, Farallon Capital Management, Invus, and others. The company raised $178M in a Series D round on Nov 21, 2022. This brings FogPharma's total funding to $362M to date.